10-K: Organon Faces Sales Decline, Goodwill Hit Amid Strategic Shift

Organon & Co. reported a 3% decrease in 2025 worldwide sales to $6.2 billion, a $301 million goodwill impairment, and identified material weaknesses in internal controls, while pursuing debt reduction and portfolio adjustments.

Summary

• Worldwide sales decreased 3% to $6.2 billion for the year ended December 31, 2025, compared to $6.4 billion in 2024.
• Net income significantly declined to $187 million in 2025 from $864 million in 2024.
• A $301 million goodwill impairment charge was recognized in the fourth quarter of 2025, primarily impacting the U.S. reporting unit due to lower-than-expected financial performance of patent-protected products and revised forward-looking projections.
• Identified material weaknesses in internal control over financial reporting related to inappropriate sales practices for Nexplanon to U.S. wholesalers and insufficient communication with financial reporting groups.
• Divested the Jada System to Laborie Medical Technologies Corporation in January 2026 for an aggregate payment of up to $465 million, comprising $440 million consideration and potential earnout payments of up to $25 million.
• Acquired U.S. regulatory and commercial rights for Tofidence (a biosimilar to Actemra) from Biogen Inc. in March 2025 for an upfront payment of $51 million.
• The FDA approved a five-year duration-of-use indication for Nexplanon in January 2026, potentially granting an additional three years of clinical investigation exclusivity in the U.S.
• Discontinued clinical development programs for investigational candidates OG-6219 (endometriosis) and OG-7191 (PCOS) in 2025 due to unmet primary efficacy endpoints or unsuitable development profiles.
• Reduced the regular quarterly dividend by 90% in 2025 to $0.02 per share to prioritize debt reduction.
• Total outstanding indebtedness was approximately $8.6 billion as of December 31, 2025.
• Net cash provided by operating activities was $700 million for 2025, a decrease from $939 million in 2024.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging period for Organon, marked by declining sales, significant goodwill impairment, and serious internal control deficiencies. While strategic divestitures and biosimilar launches offer some future potential, the immediate financial performance and governance issues are concerning.

Positives

• FDA approval of a five-year duration-of-use for Nexplanon in January 2026, potentially extending U.S. clinical investigation exclusivity by three years.
• Acquisition of U.S. commercial rights for Tofidence (tocilizumab biosimilar) from Biogen in March 2025, expanding the biosimilars portfolio.
• Launched Bildyos and Bilprevda (denosumab biosimilars) in the U.S. in 2025, and Poherdy (pertuzumab biosimilar) was approved by the FDA in November 2025.
• Sales of Vtama increased to $128 million in 2025 due to the Dermavant acquisition and new indication launches for atopic dermatitis in the U.S. and plaque psoriasis in Canada.
• Hadlima sales increased 60% in 2025 due to its U.S. launch in July 2023 and increased demand in Canada and Puerto Rico.
• Emgality sales increased 63% in 2025 as a result of acquiring distribution and promotion rights from Lilly in certain markets outside the U.S.
• Follistim AQ sales increased 11% in 2025 due to increased demand in the United States.
• Divestiture of the Jada System for up to $465 million in January 2026 is expected to strengthen the balance sheet and create future growth opportunities.
• Reduction in the dividend payout ratio and implementation of restructuring initiatives aimed at driving operational efficiencies and cost savings.
• Experienced a 46% decrease in exchange losses in 2025 due to favorable movements in certain foreign currencies relative to the U.S. dollar.
• Recognized a $69 million pre-tax gain in 2025 related to the repurchase and cancellation of 2031 Notes and the repayment and termination of the NovaQuest Funding Agreement.

Negatives

• Worldwide sales decreased 3% to $6.2 billion in 2025 compared to $6.4 billion in 2024, with international sales declining 5%.
• Net income significantly decreased to $187 million in 2025 from $864 million in 2024.
• A $301 million goodwill impairment charge was recognized in the fourth quarter of 2025, primarily affecting the U.S. reporting unit.
• Identified material weaknesses in internal control over financial reporting due to inappropriate Nexplanon sales practices and insufficient communication with financial reporting groups.
• Sales of Atozet declined 31% in 2025 primarily due to loss of exclusivity (LOE) in France, Spain, and Japan.
• Singulair sales declined 30% in 2025, mainly due to price reductions in China and Japan, and increased competition.
• NuvaRing sales declined 21% in 2025 due to the loss of a customer contract and ongoing generic competition.
• Dulera sales declined 25% in 2025 due to the loss of a customer contract and increased discount rate pressure in the U.S.
• Renflexis sales declined 8% in 2025 due to competitive pressure and unfavorable discount rates in the U.S.
• Ontruzant sales declined 30% in 2025 due to competitive pressure in the U.S. and unfavorable pricing/lower tendered volume in Brazil.
• Discontinued clinical development programs for investigational candidates OG-6219 (endometriosis) and OG-7191 (PCOS) in 2025.
• Reduced the quarterly dividend by 90% to $0.02 per share in 2025 to prioritize debt reduction.
• Cost of sales increased 8% in 2025, partly due to amortization associated with the Dermavant acquisition inventory fair value adjustment ($49 million) and increased costs to optimize manufacturing and supply network.
• Gross profit decreased 11% in 2025 due to increased costs, unfavorable pricing, volume, and product mix.
• Research and development expenses decreased 22% in 2025, reflecting a decrease in headcount-related expenses and clinical study activity, indicating limited in-house discovery capabilities.
• The SEC opened an investigation into Nexplanon sales practices following a voluntary self-disclosure.
• Nexplanon sales for 2024 included an estimated $15 million from identified improper sales practices, which adversely impacted 2025 sales as inventory levels normalized.
• The U.S. reporting unit is more susceptible to future goodwill impairment due to its current fair value over carrying amount being zero after the impairment charge.
• Incurred $95 million in restructuring costs in 2025, primarily related to headcount reductions for operational efficiencies.
• Recognized $7 million in Cost of Sales pertaining to estimated unavoidable losses associated with a long-term vendor supply contract.

Risks

• Significant global operations expose the company to risks from changes in medical reimbursement policies, multiple regulatory requirements, trade protection measures (tariffs), foreign currency fluctuations, and diminished intellectual property protection.
• The imposition of tariffs or other trade restrictions could increase costs, disrupt supply chains, and decrease profit margins, particularly for pharmaceutical imports.
• Adverse developments in the global economy, such as inflation or recession, could negatively impact business growth, margins, and the ability to collect accounts receivable.
• Changes in tax laws, including the One Big Beautiful Bill Act (OBBBA), could adversely affect effective tax rates and financial results.
• Exposure to market risk from fluctuations in currency exchange rates and interest rates, which hedging agreements may not fully mitigate.
• The self-initiated Audit Committee internal investigation and remediation plan are time-consuming and expensive, potentially leading to significant additional expenses and/or litigation.
• Identified material weaknesses in internal control over financial reporting could impact the ability to report results accurately and timely, potentially leading to misstatements, litigation, and loss of investor confidence.
• The evolving legislative and regulatory landscape for artificial intelligence (AI) poses risks related to public disclosure of confidential information, unauthorized data access, intellectual property, and compliance costs.
• Cyberattacks affecting IT systems could result in exposure of confidential information, modification of critical data, or disruption of worldwide operations.
• Inability to successfully execute the plan to deleverage the business or otherwise reduce the debt level could adversely affect operating flexibility, credit ratings, and dividend payments.
• Substantial indebtedness of approximately $8.6 billion could adversely affect financial condition and results of operations, requiring significant cash flow for debt service.
• Restrictive covenants under indebtedness could limit the ability to obtain additional financing, refinance debt, make acquisitions, pay dividends, or withstand competitive pressures.
• A significant number of privacy and data protection laws and regulations globally (e.g., GDPR, PIPL, U.S. state laws) restrict the ability to transfer, access, and use personal data, with potential for significant monetary fines.
• Dependence on key products means any adverse events affecting their markets (e.g., increased costs, generic competition, side effects, regulatory changes) could significantly impact sales, results of operations, or cash flows.
• Recent global healthcare reform initiatives and U.S. judicial decisions, laws, regulations, executive orders, and political actions (e.g., IRA, MFN pricing, 340B program changes) could adversely affect future revenues and profitability through pricing pressures and reimbursement changes.
• Failure to appoint, hire, and retain a permanent CEO, other senior management, or key employees could hinder the achievement of financial, operating, or strategic objectives.
• An impairment of goodwill could materially impact financial condition and results of operations (a $301 million impairment was recognized in 2025).
• Inability to realize benefits from investments in China and emerging markets due to economic instability, currency fluctuations, and adverse pricing controls (e.g., Volume-Based Procurement and Universal Reimbursement Payment Standard programs).
• Intense competition from competitors' products, including generic and biosimilar versions, could negatively affect sales and competitive position.
• Minimum purchase obligations under certain supply agreements could unfavorably impact financial results if minimum requirements are not met.
• Limited in-house discovery and cash to pursue early research capabilities may limit the ability to discover or develop new products or expand existing products into new markets.
• Growth could be limited by the scope of intellectual property licenses for certain health products.
• Reliance on third parties for preclinical and clinical testing, manufacturing, and distribution creates risks of non-compliance, performance failures, or misappropriation of proprietary information.
• Difficulties in connection with future acquisitions, divestitures, and other strategic actions, including integration challenges or failure to realize anticipated benefits.
• Inability to obtain and maintain required regulatory approvals or marketing authorizations for pharmaceutical products or medical devices.
• Failure to adequately demonstrate the safety and efficacy of product candidates in pre-clinical studies and clinical trials could prevent or delay development, regulatory approval, or commercialization.
• Developments following regulatory approval, such as previously unknown side effects, recalls, or negative publicity, could adversely affect sales of pharmaceutical products or medical devices.
• Disruptions at regulatory agencies (FDA, SEC) caused by funding shortages or other events could hinder their ability to perform normal business functions, impacting product development and approvals.
• Issues with product quality could have an adverse effect on the business or cause a loss of customer confidence.
• Expiry of patent protection and market exclusivity for products that contribute significantly to sales (e.g., Nexplanon in 2027/2030 in the U.S., 2026 outside the U.S.) will adversely affect the business.
• Invalidation or circumvention of patent rights would adversely affect the business, particularly for products like Nexplanon.
• Non-compliance with a variety of laws and regulations (e.g., anti-corruption, environmental, human rights, data privacy) could result in serious consequences, including substantial fines and reputational harm.
• Difficulties or delays in manufacturing due to reliance on single contract manufacturers or sole sources of supply, natural disasters, or public health crises.
• Inability to obtain sufficient components or raw materials on a timely basis or for a cost-effective price, or other supply difficulties.
• Reliance on third-party relationships and outsourcing arrangements for key aspects of the business could materially adversely affect operations.
• Non-compliance by third-party suppliers with ethical business practices or AI-related laws and regulations could harm reputation and expose the company to litigation.
• The markets for products, including the women's health market, may not develop as expected due to changes in funding, competition, or policy.
• Biosimilars carry unique regulatory risks and uncertainties due to differing and less established regulatory frameworks.
• Reliance on commercialization agreements with Samsung Bioepis, Henlius, and Biothera for the successful development and manufacture of biosimilar products.
• The FDA's shift toward 'radical transparency,' including prompt release of complete response letters and increased enforcement in advertising, could adversely impact commercial prospects and reputation.
• The global business could be negatively impacted by corporate citizenship and sustainability matters, particularly due to differing views between the U.S. and EU frameworks.
• Business and operations are subject to risks related to climate change and natural disasters, potentially impacting the supply chain, facilities, and operating costs.

Future Outlook

The company expects continued negative impact from Volume-Based Procurement (VBP) in China on its general medicines portfolio for several quarters. It anticipates ongoing focus by U.S. and non-U.S. governments on regulating drug pricing and access to medicine, which could impair its ability to compete. The One Big Beautiful Bill Act (OBBBA) and other tax law changes are expected to negatively impact the effective tax rate and results of operations. The company plans to launch Vtama in certain international markets in 2026 and beyond, and intends to launch Poherdy (pertuzumab biosimilar) in the U.S. in late 2028. Applications for Nexplanon marketing exclusivity in Latin America are expected in 2026, with potential Japanese PMDA approval for Mercilon for dysmenorrhea as early as June 2026. The company anticipates continuing to incur costs associated with the separation of its supply chain from Merck through 2031 and expects to generate positive cash flow from operations.

Management Comments

• Our business strategy is currently being executed under the leadership of Joseph Morrissey (our former Executive Vice President and Head of Manufacturing & Supply), who now serves as our Interim Chief Executive Officer (CEO), and Carrie S. Cox (the former Chairman of our Board of Directors (the Board)), who assumed the role of Executive Chair for an interim period until a permanent Chief Executive Officer is appointed.
• We also formed a Search Committee for a new permanent Chief Executive Officer and are currently evaluating candidates for the position.
• We are committed to taking steps necessary to remediate the material weaknesses as described above.
• We are actively engaged and have devoted substantial resources towards the implementation of enhanced procedures and controls and the remediation of material weaknesses in our internal control over financial reporting.
• Notwithstanding the material weaknesses described below, management has concluded that its consolidated financial statements included in this 2025 Form 10-K fairly present, in all material respects, our consolidated financial position as of December 31, 2025 and 2024 and results of operations for the years ended December 31, 2025, 2024 and 2023.
• We believe that our financing arrangements, future cash from operations, and access to capital markets will provide adequate resources to fund our future cash flow needs.

Industry Context

StockSavvy.ai notes that the pharmaceutical industry faces increasing pricing pressures globally, particularly from managed care organizations and government agencies, as evidenced by the Inflation Reduction Act (IRA) in the U.S. and Volume-Based Procurement (VBP) in China. The company's strategic pivot towards biosimilars and women's health aligns with broader industry trends seeking more affordable alternatives and addressing underserved health needs, respectively. The focus on deleveraging and optimizing manufacturing reflects a common industry response to economic headwinds and the need for operational efficiency. The increasing regulatory scrutiny on drug pricing and advertising, as highlighted by the FDA's 'radical transparency' shift, indicates a challenging environment for pharmaceutical companies.

Comparison to Industry Standards

• The 3% decline in worldwide sales for 2025 contrasts with the general growth trends seen in the broader pharmaceutical market, particularly for innovative products, where many peers are reporting modest to strong revenue increases.
• The significant goodwill impairment charge of $301 million suggests underperformance relative to initial acquisition expectations, which can be a concern for companies in the M&A-heavy pharmaceutical sector, potentially indicating overvaluation of past acquisitions compared to industry averages.
• The 90% reduction in quarterly dividend payout is a more aggressive deleveraging step compared to many established pharmaceutical companies, such as Johnson & Johnson or Merck, which often maintain stable or growing dividends, signaling a more urgent need to conserve cash.
• The discontinuation of two clinical development programs (OG-6219 for endometriosis and OG-7191 for PCOS) highlights the high-risk nature of R&D in the pharmaceutical industry, where many candidates fail in clinical trials, a common occurrence across companies like Pfizer or AstraZeneca, though the number of discontinuations in a single year can be notable.
• The identified material weaknesses in internal control over financial reporting, particularly concerning sales practices for Nexplanon, are a serious governance issue that could impact investor confidence and regulatory standing, drawing comparisons to past compliance issues at other large pharmaceutical firms that have faced similar scrutiny.

Management Changes

Corporate Governance

Legal Proceedings

• **Fosamax Litigation**: Approximately 527 cases in Federal court, 1,520 in New Jersey state court, 1 in Pennsylvania, and 218 in California state court, alleging femur fractures and other bone injuries. A Master Settlement Agreement was signed in July 2025 with New Jersey state and federal plaintiffs' lawyers for eligible clients.
• **Nexplanon/Implanon Product Liability Litigation**: Two filed product liability actions involving Implanon are pending in the Northern District of Ohio, with 56 unfiled cases tolled. One matter involving Nexplanon is pending in California state court. 17 cases are pending outside the United States (7 related to Implanon, 11 to Nexplanon).
• **Securities and Stockholder Derivative Litigation**: Two putative class action lawsuits were filed (May 27, 2025, and July 8, 2025) alleging materially false and misleading statements regarding capital allocation strategy and debt reduction. Two stockholder derivative lawsuits were consolidated on July 7, 2025, alleging breach of fiduciary duties. All actions are in the U.S. District Court for the District of New Jersey, seeking unspecified monetary damages and other relief.
• **Governmental Proceedings**: A voluntary self-disclosure was made to the U.S. Securities and Exchange Commission (SEC) on October 26, 2025, regarding an internal investigation into Nexplanon sales practices to certain wholesalers in the United States. The SEC subsequently opened an investigation into these matters.
• **Patent Litigation (Nexplanon)**: Sued Xiromed Pharma Espana, S.L. on April 2, 2025, in the U.S. District Court for the District of New Jersey, asserting infringement of U.S. Patent Nos. 8,722,037 and 9,757,552 (expiring in 2027 and 2030, respectively) after Xiromed filed an abbreviated new drug application (ANDA) for a generic Nexplanon version. This action triggered a 30-month stay of regulatory approval for Xiromed's ANDA.

Related Party Transactions

• Ongoing manufacturing and supply agreements with Merck & Co., Inc. (Merck) for certain active pharmaceutical ingredients, formulated products, and packaging, with Organon also manufacturing for Merck.
• Acquired the Oss Biotech manufacturing facility in the Netherlands from Merck in July 2025 for aggregate consideration of $25 million ($15 million paid in July 2025, $10 million to be paid in H1 2026), plus $71 million for remaining inventory.
• Interim Operating Model (IOM) agreements with Merck for marketing, import, and distribution in various jurisdictions, with one jurisdiction remaining under an IOM agreement as of December 31, 2025.
• A Tax Matters Agreement with Merck allocates responsibility for U.S. federal income, state, and foreign income, franchise, capital gain, withholding, and similar taxes, as well as non-income taxes.
• Intellectual Property License Agreements and Regulatory Agreements with Merck govern aspects of the post-Separation relationship.
• Receivables from Merck included in Accounts receivable totaled $98 million as of December 31, 2025.
• Payables to Merck included in Accounts payable totaled $337 million as of December 31, 2025.

Stakeholder Impact

• **Shareholders**: Face negative impacts from declining sales, a significant goodwill impairment, and a 90% reduction in the quarterly dividend. The ongoing SEC investigation and identified material weaknesses in internal controls introduce further uncertainty and potential for stock price volatility. Securities litigation could result in substantial monetary damages.
• **Employees**: Experienced headcount reductions (approximately 6% in 2025) due to restructuring initiatives aimed at operational efficiencies. Significant leadership changes, including an Interim CEO and Executive Chair, create a period of transition. Approximately 100 employees transferred to Laborie as part of the Jada System divestiture. Stock-based compensation plans are in place, but stock price volatility may affect employee retention and motivation.
• **Customers**: May experience changes in product availability or pricing due to loss of exclusivity for key products, increased competition, and government pricing pressures. The identified inappropriate sales practices for Nexplanon could erode trust and impact customer relationships.
• **Suppliers**: The company is subject to minimum purchase obligations under certain supply agreements, with potential for unavoidable losses if these commitments are not met. Reliance on single/sole-source suppliers creates supply chain risks that could affect product availability.
• **Creditors**: The company's substantial indebtedness of $8.6 billion and restrictive covenants under its debt agreements could affect its ability to service debt and obtain additional financing. The prioritization of deleveraging, including dividend reduction and asset divestiture, indicates a focus on improving financial health for creditors, but the overall financial performance decline presents a challenge.

Next Steps

• Continue to assess commercialization opportunities in conditions that uniquely, disproportionately, or differently affect women.
• Assess the future commercial launch of Poherdy (pertuzumab biosimilar).
• Assess opportunities to seek potential further marketing authorizations for Xaciato outside the United States.
• Evaluate candidates for a new permanent Chief Executive Officer.
• Submit applications for marketing exclusivity for Nexplanon in certain parts of the world, including Latin America, in 2026.
• Await an expected outcome in 2026 from the EU and UK Health Authorities' review of the Nexplanon five-year duration-of-use application.
• Anticipate potential Japanese PMDA approval for Mercilon for dysmenorrhea as early as June 2026.
• Intend to launch HLX11 (Poherdy) in the United States in late 2028.
• Anticipate launching Vtama in certain international markets in 2026 and beyond.
• Continue to separate the supply chain through planned exits from supply agreements with Merck through 2031.
• Implement enhanced procedures and controls and remediate material weaknesses in internal control over financial reporting.
• Enhance the Company's Annual Ethics and Policy Certifications.
• Conduct additional trainings for employees involved in Commercial and Finance regarding appropriate business practices.
• Enhance controls and implement written policies and procedures to provide governance, oversight, and guidelines for timely communication of management fee arrangements with wholesalers.
• Evaluate and enhance internal controls related to sales monitoring.
• Cooperate with the SEC investigation into Nexplanon sales practices.
• Vigorously defend patents against infringement lawsuits, such as the one against Xiromed for Nexplanon.
• Assess the impact of recently issued accounting standards ASU No. 2025-07 and ASU No. 2025-06 on consolidated financial statements.
• Evaluate the effects of ASU No. 2024-03 on related disclosures.
• Make expected contributions of approximately $15 million to pension plans during 2026.
• Make additional mandatory prepayments totaling $55 million across senior secured notes within 450 days of the January 2026 Jada System divestiture closing.
• Allocate remaining net proceeds from the Jada divestiture to voluntary prepayments of outstanding debt.
• Complete the transaction closing for the Miudella IUD license agreement, subject to regulatory approvals, customary closing conditions, and FDA approval of Miudella's supply chain.

Key Dates

Recommendation

Organon faces significant headwinds, including declining sales for key products due to loss of exclusivity, a substantial goodwill impairment, and serious internal control deficiencies leading to an SEC investigation. While strategic moves like the Jada divestiture and biosimilar launches offer long-term potential, the immediate financial performance and governance issues create considerable uncertainty. The 90% dividend cut reflects a necessary but painful deleveraging strategy. Investors should hold to monitor the effectiveness of remediation efforts, the outcome of the SEC investigation, and the company's ability to execute its revised strategy and stabilize its core business before considering further investment.

Keywords

Organon, OGN, pharmaceutical, healthcare, women's health, biosimilars, Nexplanon, Vtama, Emgality, financial results, 10-K, SEC filing, debt reduction, goodwill impairment, internal controls, corporate governance, drug pricing, market exclusivity, R&D, acquisitions, divestitures, litigation, regulatory approval, supply chain, China market, EU market, US market, oncology, immunology, contraception, fertility, established brands